2017
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiology 2017, 2: 1369-1374. PMID: 29049467, PMCID: PMC5814995, DOI: 10.1001/jamacardio.2017.3655.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisDecision Support TechniquesDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaInsuranceInsurance, HealthInsurance, Health, ReimbursementMaleMarkov ChainsMiddle AgedMyocardial InfarctionPCSK9 InhibitorsQuality-Adjusted Life YearsStrokeUnited StatesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsCurrent pricesLife yearsPrivate payersAdditional quality-adjusted life yearPreliminary cost-effectiveness analysisCost-effectiveness standardsProbabilistic sensitivity analysesCost-effectiveness analysisPrivate payer perspectiveCost-effectiveness assessmentNegative returnsHealth system perspectiveSignificant discountUS dollarsDrug pricesPatent protectionPricesStatin treatment strategiesHealth insuranceTime horizonSubtilisin/kexin type 9 inhibitors
2015
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta‐analysis
Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta‐analysis. Hepatology 2015, 62: 1417-1432. PMID: 26189925, DOI: 10.1002/hep.27999.Peer-Reviewed Original ResearchMeSH KeywordsChenodeoxycholic AcidDrug Therapy, CombinationHumansNon-alcoholic Fatty Liver DiseasePioglitazonePublication BiasRosiglitazoneThiazolidinedionesVitamin EConceptsModerate-quality evidenceNonalcoholic steatohepatitisObeticholic acidLobular inflammationBallooning degenerationVitamin ERelative riskComparative effectivenessBiopsy-proven nonalcoholic steatohepatitisLow-quality evidenceUse of pentoxifyllineIndirect treatment comparisonFuture comparative trialsHigh-quality evidenceConfidence intervalsQuality of evidenceDistinct histological featuresRecommendations AssessmentSecondary outcomesPrimary outcomeCombination therapyFibrosis stageHistological featuresComparative trialsPharmacological interventions